Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Kent Osborne

Showing results (81-90 of 158) with videos related to

Pageof 16
Sort By:
JAMA|February 15, 2017
Effect of a Scalp Cooling Device on Alopecia in Women Undergoing Chemotherapy for Breast Cancer: The SCALP Randomized Clinical TrialJulie Nangia, Tao Wang, Cynthia Osborne, et al.
Breast Cancer Research and Treatment|November 2, 2005
Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancersYee-Lu Tham, L Fernando Gomez, Syed Mohsin, et al.
Molecular Cancer Therapeutics|March 30, 2018
Trastuzumab-Resistant HER2<sup>+</sup> Breast Cancer Cells Retain Sensitivity to Poly (ADP-Ribose) Polymerase (PARP) InhibitionMonica E Wielgos, Zhuo Zhang, Rajani Rajbhandari, et al.
Cancer|July 23, 2003
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trialsJohn F R Robertson, C Kent Osborne, Anthony Howell, et al.
Journal of the National Cancer Institute|May 1, 2008
Intrinsic resistance of tumorigenic breast cancer cells to chemotherapyXiaoxian Li, Michael T Lewis, Jian Huang, et al.
Journal of the National Cancer Institute|January 15, 2009
Effect of lapatinib on the development of estrogen receptor-negative mammary tumors in miceTracy E Strecker, Qiang Shen, Yun Zhang, et al.
Cancer Research|February 28, 2016
Phosphatase PTP4A3 Promotes Triple-Negative Breast Cancer Growth and Predicts Poor Patient SurvivalPetra den Hollander, Kathryn Rawls, Anna Tsimelzon, et al.
Breast Cancer Research and Treatment|June 21, 2019
Randomized controlled trial of high-dose versus standard-dose vitamin D3 for prevention of aromatase inhibitor-induced arthralgiaPolly Niravath, Susan G Hilsenbeck, Tao Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2010
Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenograftsMothaffar F Rimawi, Lisa S Wiechmann, Yen-Chao Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2013
Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006Mothaffar F Rimawi, Ingrid A Mayer, Andres Forero, et al.
Pageof 16

Showing results (81-90 of 158) with videos related to

Sort By:
Pageof 16
JAMA|February 15, 2017
Effect of a Scalp Cooling Device on Alopecia in Women Undergoing Chemotherapy for Breast Cancer: The SCALP Randomized Clinical TrialJulie Nangia, Tao Wang, Cynthia Osborne, et al.
Breast Cancer Research and Treatment|November 2, 2005
Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancersYee-Lu Tham, L Fernando Gomez, Syed Mohsin, et al.
Molecular Cancer Therapeutics|March 30, 2018
Trastuzumab-Resistant HER2<sup>+</sup> Breast Cancer Cells Retain Sensitivity to Poly (ADP-Ribose) Polymerase (PARP) InhibitionMonica E Wielgos, Zhuo Zhang, Rajani Rajbhandari, et al.
Cancer|July 23, 2003
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trialsJohn F R Robertson, C Kent Osborne, Anthony Howell, et al.
Journal of the National Cancer Institute|May 1, 2008
Intrinsic resistance of tumorigenic breast cancer cells to chemotherapyXiaoxian Li, Michael T Lewis, Jian Huang, et al.
Journal of the National Cancer Institute|January 15, 2009
Effect of lapatinib on the development of estrogen receptor-negative mammary tumors in miceTracy E Strecker, Qiang Shen, Yun Zhang, et al.
Cancer Research|February 28, 2016
Phosphatase PTP4A3 Promotes Triple-Negative Breast Cancer Growth and Predicts Poor Patient SurvivalPetra den Hollander, Kathryn Rawls, Anna Tsimelzon, et al.
Breast Cancer Research and Treatment|June 21, 2019
Randomized controlled trial of high-dose versus standard-dose vitamin D3 for prevention of aromatase inhibitor-induced arthralgiaPolly Niravath, Susan G Hilsenbeck, Tao Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2010
Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenograftsMothaffar F Rimawi, Lisa S Wiechmann, Yen-Chao Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2013
Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006Mothaffar F Rimawi, Ingrid A Mayer, Andres Forero, et al.
Pageof 16